Multiyear SBIR funding of $3.47 million received from NIAID.

Sanaria received two multiyear SBIR grants from the NIAID to enhance the development of its whole parasite malaria vaccine.

The phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria’s malaria vaccine. The phase I grant is to develop additional methods for preserving Sanaria’s malaria vaccine.
The total first-year award for both grants is $1.21 million. Subject to satisfactory progress by Sanaria, continued funding in the second and third year will bring the total to $3.47 million.

Previous articleMDS Offers to Acquire Molecular Devices for $615 Million
Next articleSequenom and Lenetix Partner on Noninvasive Prenatal Diagnostic